# Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer

> **NCT00635596** · PHASE1 · COMPLETED · sponsor: **Amgen Research (Munich) GmbH** · enrollment: 65 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **BIOLOGICAL:** MT110

## Key facts

- **NCT ID:** NCT00635596
- **Lead sponsor:** Amgen Research (Munich) GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2014-01
- **Final completion:** 2015-01
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2015-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00635596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00635596, "Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00635596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*